A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
06/07/2021at 09:14

BioNTech/Pfizer vaccine is less effective against Delta variant

New studies indicate that the BioNTech Pfizer vaccine does not handle the Delta variant as well as other variants of the virus.
Photo: LUCY NICHOLSON/REUTERS / X90050
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The covid-19 vaccine from BioNTech/Pfizer is not nearly as effective when it comes to the new Delta variant as it is on previous versions of the virus.

This is according to preliminary studies done by the Israeli Ministry of Health, according to the Financial Times.

The studies show that BioNTech/Pfizer's vaccine is 64 percent effective in preventing fully vaccinated people from being infected with the Delta variant. This is lower than for other strains of the virus, where the vaccine is 94 percent effective.

The same studies also show that the vaccine is 93 percent effective in preventing serious illness and hospitalization.

AGC Biologics contacted minister over Danish vaccine collaboration before PM announcement 

Sanofi to establish mRNA vaccine center with 400 employees  

Pfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in Denmark 

Related articles:

  • AGC Biologics contacted minister over Danish vaccine collaboration before PM announcement

  • Sanofi to establish mRNA vaccine center with 400 employees

    For subscribers

  • Photo: Pool/Reuters/Ritzau Scanpix

    Pfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in Denmark

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of International Sales

  • Principal Laboratory Technologist

  • Commercial Director

  • Application Manager

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

See all jobs

Jobs

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of International Sales

  • Principal Laboratory Technologist

  • Commercial Director

  • Application Manager

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge